IDEXX Laboratories, Inc. (IDXX) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 0.63 to 1.47, appear driven by working capital changes, with 2025Q3 showing a $224.5M positive WC adjustment and 2025Q2 a $163.9M negative. This suggests that while earnings quality is generally solid, quarterly cash conversion is heavily influenced by timing of collections and payables, warranting a longer-term view. The most recent quarter (2026Q2) shows a healthy 1.03 ratio, aligning with net income, but investors should monitor the volatility as it may obscure underlying cash generation.

The FCF trajectory shows a clear upward trend, with 2026Q2 FCF margin of 26.5% exceeding the prior year's 21.4%, and the trailing quarters showing consistent improvement from 2025Q2's trough of 13.7%. This acceleration appears driven by strong revenue growth and operating leverage, as net income grew 15% year-over-year while capex remained stable. The FCF margin now exceeds the peer average, suggesting IDEXX is converting its earnings into cash more efficiently, which supports its capacity for shareholder returns.

CapEx/Revenue has remained remarkably consistent, ranging from 1.9% to 3.3%, with 2026Q2 at 1.9%—the lowest in the period. This suggests that IDEXX's heavy investment in its lab network and instrument base is largely complete, and current spending is primarily for maintenance and replacement. The low capital intensity, combined with high gross margins, implies that incremental revenue requires minimal additional capex, enhancing FCF generation. However, investors should monitor whether this low capex is sufficient to support the company's innovation pipeline, as R&D is expensed rather than capitalized.

The working capital line is the primary source of quarterly cash flow volatility, with large positive and negative swings that do not correlate with revenue trends. For instance, 2025Q3's $224.5M positive adjustment contrasts with 2025Q2's $163.9M negative, suggesting that IDEXX's cash conversion cycle is subject to seasonal or contractual timing. This may reflect the company's practice of offering extended payment terms to large corporate veterinary groups or the timing of inventory builds for new product launches. While the overall trend is neutral, investors should focus on annual figures to assess true working capital efficiency.

IDEXX has consistently repurchased shares each quarter, with buybacks ranging from $154.8M to $400.9M, often exceeding FCF in the same period. This aggressive buyback program, combined with zero dividends, suggests management is confident in the sustainability of cash flows and is using excess capital to reduce share count. However, the fact that buybacks exceed FCF in some quarters implies the company is either drawing down cash reserves or using debt to fund repurchases, which could strain the balance sheet if cash generation falters. The fortress-like balance sheet, with low debt, provides a cushion, but investors should monitor the sustainability of this pace.

The cumulative OCF/NI ratio over the ten-quarter period is approximately 1.06, suggesting that IDEXX's earnings are of high quality, with cash generation slightly outpacing reported net income. This is supported by the relatively low SBC (averaging under 1.5% of revenue) and stable D&A, which are non-cash charges that typically inflate the gap. The positive divergence indicates that the company is not relying on aggressive accruals to boost earnings, reinforcing the reliability of its reported profitability. However, the quarterly volatility in working capital suggests that annual figures are more meaningful for assessing this trend.